These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 7580300)

  • 1. Progress in AIDS vaccine development.
    Johnston MI
    Int Arch Allergy Immunol; 1995 Dec; 108(4):313-7. PubMed ID: 7580300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates.
    García-Arriaza J; Perdiguero B; Heeney J; Seaman M; Montefiori DC; Labranche C; Yates NL; Shen X; Tomaras GD; Ferrari G; Foulds KE; McDermott A; Kao SF; Roederer M; Hawkins N; Self S; Yao J; Farrell P; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo A; Weiss D; Lee C; Kibler K; Jacobs B; Asbach B; Wagner R; Ding S; Pantaleo G; Esteban M
    J Virol; 2015 Aug; 89(16):8525-39. PubMed ID: 26041302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
    Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
    J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C.
    Gómez CE; Nájera JL; Jiménez V; Bieler K; Wild J; Kostic L; Heidari S; Chen M; Frachette MJ; Pantaleo G; Wolf H; Liljeström P; Wagner R; Esteban M
    Vaccine; 2007 Mar; 25(11):1969-92. PubMed ID: 17224219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of V2-deleted trimeric envelope vaccine candidates from human immunodeficiency virus type 1 (HIV-1) subtypes B and C.
    Barnett SW; Srivastava IK; Ulmer JB; Donnelly JJ; Rappuoli R
    Microbes Infect; 2005 Nov; 7(14):1386-91. PubMed ID: 16275150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes.
    Egan MA; Chong SY; Rose NF; Megati S; Lopez KJ; Schadeck EB; Johnson JE; Masood A; Piacente P; Druilhet RE; Barras PW; Hasselschwert DL; Reilly P; Mishkin EM; Montefiori DC; Lewis MG; Clarke DK; Hendry RM; Marx PA; Eldridge JH; Udem SA; Israel ZR; Rose JK
    AIDS Res Hum Retroviruses; 2004 Sep; 20(9):989-1004. PubMed ID: 15585086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group m consensus env immunogen.
    Weaver EA; Lu Z; Camacho ZT; Moukdar F; Liao HX; Ma BJ; Muldoon M; Theiler J; Nabel GJ; Letvin NL; Korber BT; Hahn BH; Haynes BF; Gao F
    J Virol; 2006 Jul; 80(14):6745-56. PubMed ID: 16809280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccines based on Nef and on Nef/DeltaV2 Env.
    Erfle V; Goebel FD; Guzman CA; Le Grand R
    Microbes Infect; 2005 Nov; 7(14):1400-4. PubMed ID: 16243564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The rationale behind a vaccine based on multiple HIV antigens.
    Rollman E; Bråve A; Boberg A; Gudmundsdotter L; Engström G; Isaguliants M; Ljungberg K; Lundgren B; Blomberg P; Hinkula J; Hejdeman B; Sandström E; Liu M; Wahren B
    Microbes Infect; 2005 Nov; 7(14):1414-23. PubMed ID: 16257558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced humoral HIV-1-specific immune responses generated from recombinant rhabdoviral-based vaccine vectors co-expressing HIV-1 proteins and IL-2.
    McGettigan JP; Koser ML; McKenna PM; Smith ME; Marvin JM; Eisenlohr LC; Dietzschold B; Schnell MJ
    Virology; 2006 Jan; 344(2):363-77. PubMed ID: 16226782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.
    Kmieciak D; Bolesta E; Naito T; Gzyl J; Kaneko Y; Kozbor D
    J Hum Virol; 2001; 4(6):306-16. PubMed ID: 12082397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Criteria for selection of HIV vaccine candidates--general principles.
    Ensoli B
    Microbes Infect; 2005 Nov; 7(14):1433-5. PubMed ID: 16213181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progress toward an HIV vaccine.
    Letvin NL
    Annu Rev Med; 2005; 56():213-23. PubMed ID: 15660510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors.
    Casimiro DR; Bett AJ; Fu TM; Davies ME; Tang A; Wilson KA; Chen M; Long R; McKelvey T; Chastain M; Gurunathan S; Tartaglia J; Emini EA; Shiver J
    J Virol; 2004 Oct; 78(20):11434-8. PubMed ID: 15452269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccines based on the native HIV Tat protein and on the combination of Tat and the structural HIV protein variant DeltaV2 Env.
    Ensoli B; Cafaro A; Caputo A; Fiorelli V; Ensoli F; Gavioli R; Ferrantelli F; Cara A; Titti F; Magnani M
    Microbes Infect; 2005 Nov; 7(14):1392-9. PubMed ID: 16243561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pseudovirion particle production by live poxvirus human immunodeficiency virus vaccine vector enhances humoral and cellular immune responses.
    Chen X; Rock MT; Hammonds J; Tartaglia J; Shintani A; Currier J; Slike B; Crowe JE; Marovich M; Spearman P
    J Virol; 2005 May; 79(9):5537-47. PubMed ID: 15827168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poxvirus vectors as HIV/AIDS vaccines in humans.
    Gómez CE; Perdiguero B; Garcia-Arriaza J; Esteban M
    Hum Vaccin Immunother; 2012 Sep; 8(9):1192-207. PubMed ID: 22906946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection of monkeys vaccinated with vpr- and/or nef-defective simian immunodeficiency virus strain mac/human immunodeficiency virus type 1 chimeric viruses: a potential candidate live-attenuated human AIDS vaccine.
    Igarashi T; Ami Y; Yamamoto H; Shibata R; Kuwata T; Mukai R; Shinohara K; Komatsu T; Adachi A; Hayami M
    J Gen Virol; 1997 May; 78 ( Pt 5)():985-9. PubMed ID: 9152414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospects for an AIDS vaccine.
    Girard M
    Cancer Detect Prev; 1990; 14(3):411-3. PubMed ID: 2117487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.